Human Trials

Centrexion’s pain drug CNTX-4975 yields positive results in phase 2b knee osteoarthritis trial

Centrexion Therapeutics reported positive 6-month efficacy data from the Phase 2b TRIUMPH trial demonstrating durable response of CNTX-4975 for treatment of chronic pain associated with knee osteoarthritis.

REMD’s lead candidate succeeds in phase 1 trial in type 1 diabetes patients

REMD Biotherapeutics (REMD Bio) and its subsidiary Cosci-REMD Biotherapeutics (Cosci-REMD Bi) have announced positive results from a phase 1 clinical study of its lead candidate REMD-477 in patients with type 1 diabetes.

Probiodrug unveils encouraging results of phase 2a SAPHIR study in AD patients

Probiodrug has reported positive results for its PQ912 candidate in a Phase 2a SAPHIR study in early Alzheimer’s disease (AD) patients.

Merck and Pfizer’s ertugliflozin meets primary endpoints in two type 2 diabetes studies

Merck, in partnership with Pfizer, announced that two phase 3 studies of ertugliflozin, an investigational oral SGLT-2 inhibitor in development to help enhance glycemic control in adults with type 2 diabetes, met their primary endpoints.

Teva’s migraine candidate fremanezumab succeeds in second phase III study

Teva Pharmaceutical Industries’ Fremanezumab has meets all primary & secondary endpoints across both monthly and quarterly dosing regimens in phase III study in episodic migraine prevention.

Juno announces updated data from trial of JCAR017 in r/r aggressive B cell NHL

Juno Therapeutics has presented updated TRANSCEND NHL 001 trial data showing high durable response rates in patients with relapsed or refractory CD19+ aggressive non-hodgkin lymphoma at the 2017 Annual Meeting of the American Society for Clinical Oncology (ASCO).

Teva’s phase 3 study of migraine drug fremanezumab yields positive results

Teva Pharmaceutical Industries has reported positive results from a Phase III HALO study for its migraine drug fremanezumab.

Lysogene completes patient enrollment in first observational study in MPS IIIA

Biopharmaceutical firm Lysogene has completed enrollment of patients in its “Sanfilippo A Multi-national Observational Study” (SAMOS).

Neurocrine’s Ingrezza fails in phase II Tourette syndrome study

Neurocrine Biosciences said that the initial phase II Tourette syndrome T-Force GREEN study of INGREZZA (valbenazine), a small molecule VMAT2 inhibitor, did not meet its primary endpoint.